Boston Trust Walden’s BIO-REFERENCE LABS INC-NEW- BRLI Stock Holding History

Boston Trust Walden’s Portfolio BRLI Stock Details BRLI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2015 Q3	–	Sell	-959,914	Closed	-$39.6M	–	361
2015 Q2	$39.6M	Sell	959,914 -328,701	-26%	-$11.8M	0.6%	52
2015 Q1	$45.4M	Sell	1,288,615 -6,703	-0.5%	-$227K	0.67%	46
2014 Q4	$41.6M	Buy	1,295,318 +12,774	+1%	+$369K	0.62%	53
2014 Q3	$36M	Buy	1,282,544 +45,873	+4%	+$1.4M	0.56%	62
2014 Q2	$37.4M	Buy	1,236,671 +35,492	+3%	+$980K	0.54%	74
2014 Q1	$33.2M	Buy	1,201,179 +17,910	+2%	+$469K	0.49%	94
2013 Q4	$30.2M	Buy	+1,183,269	New	+$36.5M	0.44%	101

Other funds holding BRLI

SAM

Shell Asset Management The Hague, Netherlands $996M AUM 26.19% 1-Year Est. Return

Boston Trust Walden's BRLI Position: Q3 2015 in Review

Boston Trust Walden sold out of BIO-REFERENCE LABS INC-NEW- (BRLI) in Q3 2015, closing a stake of 959,914 shares — an estimated $39.6M sold.

Boston Trust Walden first reported a position in BRLI in Q4 2013 and held it in 7 quarters. The position peaked at $45.4M in Q1 2015. 1 fund tracked by Wall St. Rank holds BRLI as of Q3 2015.

Boston Trust Walden reported no remaining BIO-REFERENCE LABS INC-NEW- position as of Q3 2015 after selling out during the quarter.
Boston Trust Walden sold 959,914 BIO-REFERENCE LABS INC-NEW- shares in Q3 2015, an estimated $39.6M.
Boston Trust Walden first reported a position in BIO-REFERENCE LABS INC-NEW- in Q4 2013 and held it in 7 quarters.
Boston Trust Walden's BIO-REFERENCE LABS INC-NEW- position peaked at $45.4M in Q1 2015.
1 fund tracked by Wall St. Rank held BIO-REFERENCE LABS INC-NEW- as of Q3 2015.

Based on Boston Trust Walden's 13F filing for Q3 2015, filed 29 Oct 2015.